Ultomiris showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks
Results from CHAMPION-NMOSD trial demonstrated Ultomiris reduced the risk of relapse in AQP4 Ab+ NMOSD by 98.6% compared to placebo.Ultomiris also showed a lower proportion of patients experiencing clinically important worsening in Hauser Ambulatory Index score, a measure of patient mobility.Strong results across several subgroup analyses add to growing body of evidence supporting C5 inhibition in NMOSD.Detailed positive results from the Phase III CHAMPION-NMOSD trial showed that Ultomiris (ravulizumab) significantly reduced relapse risk in adults with anti-aquaporin-4 (AQP4) antibody-